Sun Pharma to launch first-in-class oral lipid-lowering drug in India

pharmafile | May 19, 2022 | News story | Business Services |   

Sun Pharma has said that it is planning to launch a medication to reduce low-density lipoprotein (LDL) cholesterol.

The Mumbai-based drug major said that one of its wholly-owned subsidiaries plans to launch a first-in-class oral drug, Bempedoic Acid, for reducing LDL cholesterol in India.

The company will launch the drug under the name Brillo. The drug is a first-in-class drug which has a new mechanism of action compared to the currently available lipid-lowering agents.

Advertisement

The drug is indicated for those who have an inherited genetic disorder which causes high cholesterol levels or established heart disease where cholesterol levels remain high, in spite of lifestyle changes and the use of maximum tolerated dose of statins.

Some patients with high levels of cholesterol may respond inadequately to statins, and there is also a set of patients who are intolerant to statins. Bempedoic acid can therefore be a useful treatment option for such patients.

High cholesterol can increase a person’s risk of heart and circulatory diseases such as heart attack and stroke.

The burden of heart disease at 272 per 1,000,000 population in India is higher than the global average of 235 per 1,000,000 population.

The product is a novel treatment option which will hopefully help manage high LDL cholesterol in patients with heart diseases, which is growing at an alarming rate, according to Sun Pharma CEO, Kirti Ganorkar.

Lina Adams

Related Content

No items found
The Gateway to Local Adoption Series

Latest content